All News
EULAR 2024 Rheumatology Roundup (6.21.2024)
Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna
Read Article
Abatacept Misses on Shingrix Response
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
https://t.co/3Tp777HVTD https://t.co/PRrjm65nFK
Dr. John Cush RheumNow ( View Tweet)
"AMPLIFIED study:
abatacept vs adalimumab in RF+ACPA+ early RA
Not a single blink of difference.
Maybe for high CCP titre but the inverse for low CCP.
Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 Rheumatology Roundup
Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna
https://t.co/TqEAuk0PGp https://t.co/erRZ3cLxhu
Dr. John Cush RheumNow ( View Tweet)
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024
Dr. John Cush RheumNow ( View Tweet)
Tapering Treatment for Lupus
Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus.
https://t.co/ijy5OwIoCe https://t.co/7yQIxW70Zd
Dr. John Cush RheumNow ( View Tweet)
Cognitive Function in Older Adults: Worse in Lupus
Dr. Mrinalini Dey discusses abstract POS0730 presented at Eular 2024 in Vienna, Austria.
https://t.co/zedGdNbHw4 https://t.co/DIHvkEZRVk
Dr. John Cush RheumNow ( View Tweet)
A Puzzling Era in Global Drug Development?
Dr. Eric Ruderman offers his observation regarding a puzzling global drug development observation, at Eular 2024 in Vienna, Austria.
https://t.co/A4KQovIt3u https://t.co/TQHJnSkIod
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
Dr. John Cush RheumNow ( View Tweet)
The path to new technologies in rheumatology must be beset with caution
https://t.co/rostCE3UFT https://t.co/bn352RmrN8
Dr. John Cush RheumNow ( View Tweet)
Enhance your clinical practice with insights from the EULAR 2024 Poster Hall Presentations, now on https://t.co/V10S4oVFsv. This year's conference showcases pivotal research in rheumatology. Visit https://t.co/58cJsSROsE to stay at the forefront of medical innovation. https://t.co/jbbufRQ6MW
Dr. John Cush RheumNow ( View Tweet)
Rituximab vs. Tocilizimab for Scleroderma: Which is Better?
Dr. Janet Pope discusses abstract OP0295 presented at Eular 2024 in Vienna, Austria.
https://t.co/70YF2wxwj5 https://t.co/8BHCafFs3u
Dr. John Cush RheumNow ( View Tweet)
DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
https://t.co/gKJRygBeq0 https://t.co/2NTNYJLPNZ
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 Daily Recap: Days 1 & 2
Dr. Jack Cush moderates EULAR 2024 RECAP for days 1 & 2 with Drs. Mrinalini Day and Yuz Yusof in Vienna, Austria.
https://t.co/gRMVUXhTxw https://t.co/YV8vjVUCJn
Dr. John Cush RheumNow ( View Tweet)
Rituximab to Treat Systemic Features of Sjogren's
Dr. Yuz Yusof discusses abstract OP0076 presented at Eular 2024 in Vienna, Austria.
https://t.co/9oJNz12cCI https://t.co/bZxpbf3PT9
Dr. John Cush RheumNow ( View Tweet)
Update on Sjogren's disease trials
With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease.
https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 – Day 4 Report
The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations. Below is a synopsis of the half-day's action.
https://t.co/1lQcu1beOm https://t.co/QHMcFzaG48
Dr. John Cush RheumNow ( View Tweet)
Select your GCA Therapy
Dr. David Liew discusses LBA0001 presented at Eular 2024 in Vienna, Austria.
https://t.co/TPBeU7KaEq https://t.co/09uEzM3Kkd
Dr. John Cush RheumNow ( View Tweet)
Predicting Palindromic Prognosis
Dr. David Liew discusses abstract OP0127 at Eular 2024 in Vienna, Austria.
https://t.co/Nc0XymI24l https://t.co/69qdLh63ct
Dr. John Cush RheumNow ( View Tweet)
Giant Cell Arteritis and Polymyalgia Rheumatica Update
Dr. Janet Pope discusses abstracts LBA0001, OP0233, OP0261 and POS0280 at Eular 2024 in Vienna, Austria.
https://t.co/0V9Sle0GMU https://t.co/ixeT8L562C
Dr. John Cush RheumNow ( View Tweet)
